Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Comparison of Brodalumab Versus Guselkumab in Adult Subjects With Moderate-to-severe Plaque Psoriasis and Inadequate Response to Ustekinumab

NCT04533737 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT04533737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04533737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Comparison of Brodalumab Versus Guselkumab in Adult Subjects With Moderate-to-severe Plaque Psoriasis and Inadequate Response to Ustekinumab
Lead sponsor
LEO Pharma
Phase
Phase 4
Overall status
Terminated
Start date
December 17, 2020
Completion date
December 7, 2022
Enrollment
113 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis, psoriasis, psoriasis vulgaris